Guidance, NICE advice and quality standards in development | Guidance

Showing 11 to 20 of 407

Sort by

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Alpelisib with olaparib for treating BRCA wild-type platinum-refractory or -resistant ovarian, fallopian tube or primary peritoneal cancer after 1 to 3 previous treatments [ID6247]	Technology appraisal guidance	TBC
ALXN1840 for treating Wilson disease [ID6422]	Technology appraisal guidance	TBC
Amivantamab with carboplatin and pemetrexed for untreated EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer [ID5110]	Technology appraisal guidance	TBC
Apadamtase alfa for treating congenital thrombotic thrombocytopenic purpura caused by ADAMTS-13 deficiency [ID6192]	Technology appraisal guidance	TBC
Apalutamide with gonadotrophin-releasing hormone agonist and radiotherapy for treating high-risk, localised or locally advanced prostate cancer [ID6215]	Technology appraisal guidance	TBC
Apraglutide for treating short bowel syndrome [ID6533]	Technology appraisal guidance	TBC
Arimoclomol for treating Niemann-Pick disease Type C [ID1312]	Highly specialised technology	TBC
Artificial intelligence (AI) technologies to assist histopathology for breast cancer diagnosis [ID6732 ]	Technology appraisal guidance	TBC
Artificial intelligence (AI) technologies to assist histopathology for prostate cancer diagnosis [ID6684]	Technology appraisal guidance	TBC
Artificial Intelligence (AI)-assisted echocardiography analysis and reporting to support the diagnosis and monitoring of heart failure: Early Value Assessment	Health technology evaluation	20 May 2026